This new HFSA offering will focus on the role of devices in heart failure. This 90-minute seminar will include four didactic lectures with panel Q&A to be held after each lecture. Topics include the current state of devices in HF, how to start a device program and implement device strategies into clinical management, how to set-up a remote monitoring clinic, and novel devices entering testing and trials.

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the current landscape of devices in heart failure treatment, including emerging trends and future possibilities.
2. Implement device-based strategies into clinical management and explore the steps and considerations involved in starting a device heart failure program.
3. Explain the principles and steps involved in setting up a remote monitoring clinic for heart failure patients.
4. Identify novel devices entering testing for heart failure treatment.

Program Planners:

• Marat Fudim, MD

Faculty:

• Daniel Bensimhon, MD
• Liviu Klein, MD
• Shelley Hall, MD
• Andrew Sauer, MD

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculties, planners and/or accreditors with the ability to control content for this activity have listed the below disclosures:

• Marat Fudim -- Consultant Roles:  Axon Therapies, Alleviant, CVRX, Impulse Dynamics, Abbott, Endotronix.
• Shelley Hall -- Consultant Roles:  Device Manufacturer: Abbott, CVRX.  Diagnostic Labs:  Care DX, Natera, 
• Liviu Klein -- Consultant Roles:  Device Manufacturers/Disbributors: Abbott, Boston Scientific, Edwards, Medtronic
• Daniel Bensimhon -- Advisory Board, Equity: Sensible Medical.  Consulting: Caption Health.  Consulting/Stock Ownership: ScPharmaceuticals.  Advisory Boards/Stock Options:  Corstasis, AquaPass.  Founder/Equity: Ventricle Health.  Speaker Bureau Relationships: Astrazenca, Bayer, Boehringer Ingelheim/Lilly, Janssen, Pfizer, ScPharmaceuticals, Merck
• Andrew Sauer -- Research Funding from Bayer, National Lead Investigator, Scientific Oversight with ARO
  REDEFINE-HF, CONFIRMATION-HF, FINALITY-HF (MOONRAKER PROGRAM) Senior Scientific Advisor, Acorai, CAPTURE-HF study, POC Hemodynamics Senior Scientific Advisor, General Prognostics, TRIBE-2 study and program National Lead Investigator and Study Medical Monitor, CSL-Vifor CARE-HK Registry Steering Committee, Rivus, HuMAIN Phase II study of HU6 Metabolic Accelerator in HFpEF Steering Committee, Boston Scientific, LUX-DX-TRENDS Heart Logic study, Medical Optimization Committee, TRILUMINATE Study, Abbott; Advising for Amgen, Phase III Clinical Trial Program: Obesity in HFpEF Pharmacotherapy; Advising for 35Pharma, Phase I/II Clinical Trial Program: Obesity in HFpEF Pharmacotherapy; Advising for Regeneron, Phase II Clinical Trial Program: Obesity in HFpEF Pharmacotherapy; Senior Advisor: I own stock in ISHI, a privately owned digital health services company
  Senior Advisor: I own stock in Pulsli, a privately owned digital health technology company; Advising / Research Funding: Abbott, Impulse Dynamics, Pfizer, Astra Zeneca, CSL-Vifor, Edwards.

Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

 
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Successful completion of this CME activity, includes participation in the evaluation component.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum of 1.50 contact hours.

 
The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Learners should claim only the credit commensurate with the extent of their participation in the activity.